Challenges of detecting measurable/minimal disease in acute leukemia

Abstract

Measurable/minimal residual disease (MRD) tracking has emerged as a powerful tool for assessing treatment response and predicting outcomes in acute leukemia. However, the clinical and technological challenges associated with MRD tracking must be addressed to improve its utility in routine patient care. This review article aims to provide a summary of the different MRD methodologies used in acute leukemia. It highlights the strengths, diagnostic pitfalls, and clinical utility associated with MRD tracking in this rapidly evolving field.

Keywords: Acute myeloid leukemia; B lymphoblastic leukemia; Flow cytometry; Measurable residual disease; Minimal residual disease; Next generation sequencing.